Consenso sobre o uso de Avastin® para o tratamento da retinopatia da prematuridade na Argentina
DOI:
https://doi.org/10.70313/2718.7446.v16.nS1.364Palavras-chave:
retinopatia da prematuridade, ROP, antiangiogênicos, Avastin, ArgentinaResumo
Entende-se por uso off-label o uso de um medicamento já aprovado para uma indicação específica, mas que é utilizado para uma prescrição diferente daquela contemplada em sua ficha técnica. O uso off-label do produto Avastin® (Roche) é aceito sob o aspecto bioético para seu uso em diversas patologias oftalmológicas, considerando sua função antiangiogênica. A retinopatia da prematuridade (ROP), uma doença ocular causada por comprometimento da vasculogênese retiniana, é a principal causa de cegueira na infância. Afeta apenas bebês prematuros e especialmente aqueles com menos de 1.500 g de peso ao nascer e/ ou crianças com 32 semanas de idade gestacional. O aparecimento desta doença pode ser atenuado com diferentes ações. Da mesma forma, há vários anos a comunidade científica começou a usar o Avastin® (Roche) off-label para o tratamento de algumas formas de ROP, isoladamente ou associado à fotocoagulação a laser. O presente trabalho teve como objetivo avaliar aspectos relacionados à segurança, eficácia e implicações econômicas do uso de Avastin em ROP, no território nacional argentino. Aplicou-se uma metodologia em formato de consenso científico através da qual, após análise das evidências disponíveis e com base na opinião de especialistas, concluiu-se que a escolha deste produto se sustenta tanto por ser economicamente mais acessível como por demonstrar equivalência em aspectos de segurança e não inferioridade terapêutica em comparação com outros antiangiogênicos.
Referências
Chiang MF, Quinn GE, Fielder AR et al. International classification of retinopathy of prematurity, third edition. Ophthalmology 2021; 128: e51-e68.
Wood EH, Chang EY, Beck K et al. 80 years of vision: preventing blindness from retinopathy of prematurity. J Perinatol 2021; 41: 1216-1224.
Sabri K, Ells AL, Lee EY et al. Retinopathy of prematurity: a global perspective and recent developments. Pediatrics 2022; 150: e2021053924.
Esandi ME, Lomuto C, Alda E. Desigualdades en oftalmología: la atención de la retinopatía del prematuro como caso de análisis. En: Ortiz Basso T, Visintin P. Responsabilidad social de los oftalmólogos. Buenos Aires: Consejo Argentino de Oftalmología, 2022, p. 159-175. (Colección PROECO).
Herrod SK, Adio A, Isenberg SJ, Lambert SR. Blindness secondary to retinopathy of prematurity in Sub-Saharan Africa. Ophthalmic Epidemiol 2022; 29: 156-163.
De las Rivas Ramírez N, Luque Aranda G, Rius Díaz F et al. Risk factors associated with retinopathy of prematurity development and progression. Sci Rep 2022; 12: 21977.
Yu CW, Popovic MM, Dhoot AS et al. Demographic risk factors of retinopathy of prematurity: a systematic review of population-based studies. Neonatology 2022; 119: 151-163.
Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2018; 1: CD009734. Oftalmología Clínica y Experimental ● ISSNe 2718-7446 ● Volumen 16 ● Suplemento (2023) eS11
Jang JH, Kang YK, Park HS et al. Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity. BMJ Open Ophthalmol 2023; 8: e001166.
Hartnett ME, Stahl A. Laser versus anti-VEGF: a paradigm shift for treatment-warranted retinopathy of prematurity. Ophthalmol Ther 2023; s40123-023-00744-7.
Administración Nacional de Medicamentos, Alimentos y Tecnologías Médicas (ANMAT). Informe ultrarrápido de evaluación de tecnología sanitaria (IURETS). Buenos Aires: ANMAT, 2016. Disponible en: https:// www.entrerios.gov.ar/msalud/wp-content/ uploads/2016/05/BZM-NF2_informe_final. pdf
Chang E, Josan AS, Purohit R et al. A Network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity. Ophthalmology 2022; 129: 1389-1401.
Borrone R. Consentimiento informado para el tratamiento y seguimiento de la retinopatía del prematuro (ROP). En su: Consentimientos informados oftalmológicos. Buenos Aires: Consejo Argentino de Oftalmología (CAO), 2018. Disponible en: https://oftalmologos.org.ar/images/herramientas/rop/5-1-consentimiento-informado-tratamiento-seguimiento-de-rop.pdf
Lomuto C, Alda E, Avila A et al. Retinopatía del prematuro en Argentina 2020 [en línea]. Buenos Aires: Ministerio de Salud. Dirección de Salud Perinatal y Niñez. Grupo ROP). Disponible en: https://oftalmologos.org.ar/ images/2021/202105-Estadisticas-del-Registro-ROP2020.pdf
Argentina. Ministerio de Salud. Grupo ROP Argentina. Guía de práctica clínica para la prevención, diagnóstico y tratamiento de la retinopatía del prematuro (ROP). Buenos Aires: Ministerio de Salud, 2016. Disponible en: https://bancos.salud.gob.ar/sites/default/ files/2018-10/0000000723cnt-guia-rop-2016. pdf
Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926.
Esandi ME, Durán L. Uriarte E, Lauronce M. Actualización de recomendaciones clave de la Guía de práctica clínica para la prevención, diagnóstico y tratamiento de la retinopatía del prematuro (ROP) en el marco del contrato con OPS. Buenos Aires: para el Ministerio de Salud, reporte interno CON21-00017300, marzo 2021.
Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38: 1258-1264.
Michels S, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-1047.
Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
Ahmadieh H, Moradian S, Malihi M. Rapid regression of extensive retinovitreal neovascularization secondary to branch retinal vein occlusion after a single intravitreal injection of bevacizumab. Int Ophthalmol 2005; 26: 191-193.
Rosenfeld PJ, Brown DM, MARINA Study Group et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
Brown DM, Kaiser PK, ANCHOR Study Group et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006; 19: 361-372.
Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol 2007; 55: 417-420.
Ip MS, Scott IU, American Academy of Ophthalmology et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Oftalmología Clínica y Experimental ● ISSNe 2718-7446 ● Volumen 16 ● Suplemento (2023) eS12 Academy of Ophthalmology. Ophthalmology 2008; 115: 1837-1846.
Li Z, Zhang Y, Liao Y et al. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol 2018; 18: 19.
Tan QQ, Christiansen SP, Wang J. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review. PLoS One 2019; 14: e0225643.
Kaushal M, Razak A, Patel W et al. Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol 2021; 41: 1225-1235.
Pertl L, Steinwender G, Mayer C et al. A systematic review and meta-analysis on the safety of vascular endothelial growth factor (VEGF) inhibitors for the treatment of retinopathy of prematurity. PLoS One 2015; 10: e0129383.
Kong Q, Ming WK, Mi XS. Refractive outcomes after intravitreal injection of antivascular endothelial growth factor versus laser photocoagulation for retinopathy of prematurity: a meta-analysis. BMJ Open 2021; 11: e042384.
Wang SD, Zhang GM; Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a meta-analysis. Int J Ophthalmol 2020; 13: 806-815.
Popovic MM, Nichani P, Muni RH et al. Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: a meta-analysis of 3.701 eyes. Surv Ophthalmol 2020; 66: 572-584.
Tsai CY, Yeh PT, Tsao PN et al. Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis. Ophthalmology 2021; 128: 877-888.
Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-615.
Autrata R, Krejcírová I, Senková K et al. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol 2012; 22: 687-694.
Geloneck MM, Chuang AZ; BEAT-ROP Cooperative Group et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014; 132: 1327-1333.
Lepore D, Quinn GE, Molle F et al. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 2014; 121: 2212-2219.
Moran S, O’Keefe M, Hartnett C et al. Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity. Acta Ophthalmol 2014; 92: e496-e497.
O’Keeffe N, Murphy J, O’Keefe M, Lanigan B. Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: a 5 year follow up. Ir Med J 2016; 109: 355.
Karkhaneh R, Khodabande A, Riazi-Eafahani M et al. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity. Acta Ophthalmol 2016; 94: e417-e420.
Zhang G, Yang M; Shenzhen Screening for Retinopathy of Prematurity Cooperative Group et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina 2017; 37: 710-717.
Lepore D, Quinn GE, Molle F et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology 2018; 125: 218-226.
Kennedy KA, Mintz-Hittner HA; BEATROP Cooperative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS 2018; 22: 61-65.e1.
Roohipoor R, Torabi H, Karkhaneh R, Riazi-Eafahani M. Comparison of intravitreal bevacizumab injection and laser photocoagulation Oftalmología Clínica y Experimental ● ISSNe 2718-7446 ● Volumen 16 ● Suplemento (2023) eS13 for type 1 zone II retinopathy of prematurity. J Curr Ophthalmol 2018; 31: 61-65.
Stahl A, Lepore D, Fielder A et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 2019; 394: 1551-1559.
Marlow N, Stahl A; RAINBOW Investigators Group et al. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health 2021; 5: 698-707.
Patel NA, Acaba-Berrocal LA; Retinopathy of Prematurity Injection Consortium (ROPIC) et al. Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity: a multicenter study. Ophthalmology 2023; 130: 373-378.
Kychenthal BA, Dorta SP (eds.). Retinopathy of prematurity: current diagnosis and management. Cham, Suiza: Springer, 2017.
Larcher P, Franz G, Boggetti HJ. Eficacia de la concentración de bevacizumab fraccionado y utilizado durante un año en el tratamiento de AP-ROP en la Neonatología del Hospital Regional Ramón Carrillo. RAOI: Rev Arg Oftalmol Infant 2020; 1:18- 19. Disponible en: https://saoi.org.ar/wp-content/ uploads/2023/02/RAOI-V1-N1-ISSN.pdf
Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology 2015; 122: 1008-1015.
Frosini S, Franco F, Vicini G et al. Efficacy and safety of intravitreal bevacizumab for the treatment of retinopathy of prematurity: a single-center retrospective review. J Matern Fetal Neonatal Med 2022; 35: 3337-3342.
Stahl A, Sukgen EA; FIREFLEYE Study Group et al. Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial. JAMA 2022; 328: 348- 359.
Tsiropoulos GN, Seliniotaki AK, Haidich AB et al. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review. Int Ophthalmol 2023; 43: 1027-1062.
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2023 Consejo Argentino de Oftalmología
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial-SemDerivações 4.0.
Con esta licencia no se permite un uso comercial de la obra original, ni la generación de obras derivadas. Las licencias Creative Commons permiten a los autores compartir y liberar sus obras en forma legal y segura.
